Total Payments
$462,940
2024 Payments
$65,785
Companies
72
Transactions
1,549
Medicare Patients
8,383
Medicare Billing
$1.3M
Payment Breakdown by Category
Other$376,238 (81.3%)
Food & Beverage$30,189 (6.5%)
Travel$29,377 (6.3%)
Consulting$26,750 (5.8%)
Education$385.77 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $345,938 | 198 | 74.7% |
| Honoraria | $30,300 | 14 | 6.5% |
| Food and Beverage | $30,189 | 1,201 | 6.5% |
| Travel and Lodging | $29,377 | 117 | 6.3% |
| Consulting Fee | $26,750 | 9 | 5.8% |
| Education | $385.77 | 10 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $171,564 | 268 | $0 (2024) |
| Amgen Inc. | $91,951 | 143 | $0 (2023) |
| Allergan, Inc. | $35,202 | 69 | $0 (2022) |
| Lilly USA, LLC | $33,951 | 116 | $0 (2024) |
| ARGENX US, INC. | $29,080 | 48 | $0 (2024) |
| ABBVIE INC. | $20,629 | 101 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $20,082 | 33 | $0 (2021) |
| UCB, Inc. | $18,475 | 120 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $12,313 | 88 | $0 (2020) |
| Eli Lilly and Company | $12,187 | 23 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $65,785 | 222 | Alexion Pharmaceuticals, Inc. ($26,018) |
| 2023 | $59,068 | 262 | Alexion Pharmaceuticals, Inc. ($27,364) |
| 2022 | $39,786 | 175 | Alexion Pharmaceuticals, Inc. ($13,444) |
| 2021 | $68,385 | 186 | Biohaven Pharmaceuticals, Inc. ($20,082) |
| 2020 | $70,399 | 190 | Allergan, Inc. ($31,625) |
| 2019 | $69,116 | 194 | Alexion Pharmaceuticals, Inc. ($40,189) |
| 2018 | $68,214 | 212 | Alexion Pharmaceuticals, Inc. ($31,405) |
| 2017 | $22,188 | 108 | Alexion Pharmaceuticals, Inc. ($9,833) |
All Payment Transactions
1,549 individual payment records from CMS Open Payments — Page 1 of 62
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $27.92 | General |
| Category: Neurology | ||||||
| 12/16/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: PAIN | ||||||
| 12/09/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Neuroscience | ||||||
| 12/05/2024 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: Neurology | ||||||
| 12/02/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: Neurology | ||||||
| 12/02/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Neuroscience | ||||||
| 11/20/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $32.96 | General |
| Category: Neurology | ||||||
| 11/20/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $31.73 | General |
| Category: Neurology | ||||||
| 11/18/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Neuroscience | ||||||
| 11/18/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Neuroscience | ||||||
| 11/15/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Neuroscience | ||||||
| 11/15/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Neuroscience | ||||||
| 11/13/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Neuroscience | ||||||
| 11/13/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | Cash or cash equivalent | $119.27 | General |
| Category: Neuroscience | ||||||
| 11/13/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $18.64 | General |
| Category: Neuroscience | ||||||
| 11/11/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $22.38 | General |
| Category: Neuroscience | ||||||
| 11/05/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $29.98 | General |
| Category: Neurology | ||||||
| 10/30/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $5.54 | General |
| Category: NEUROSCIENCE | ||||||
| 10/28/2024 | UCB, Inc. | Zilbrysq (Drug) | Food and Beverage | In-kind items and services | $24.29 | General |
| Category: Neurology | ||||||
| 10/23/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $25.83 | General |
| Category: PAIN | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: Neurology | ||||||
| 10/18/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $29.65 | General |
| Category: Neurology | ||||||
| 10/16/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $32.84 | General |
| Category: Neurology | ||||||
| 10/14/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 2,859 | 27,764 | $2.8M | $529,354 |
| 2022 | 16 | 2,299 | 14,600 | $1.9M | $351,698 |
| 2021 | 16 | 1,732 | 2,193 | $1.1M | $219,750 |
| 2020 | 13 | 1,493 | 1,900 | $885,625 | $172,916 |
Total Patients
8,383
Total Services
46,457
Medicare Billing
$1.3M
Procedure Codes
64
All Medicare Procedures & Services
64 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 715 | 1,404 | $789,048 | $140,661 | 17.8% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 28 | 20,145 | $481,080 | $99,793 | 20.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 333 | 333 | $325,008 | $56,734 | 17.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 389 | 389 | $283,970 | $50,293 | 17.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 425 | 611 | $242,567 | $42,970 | 17.7% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 157 | 306 | $132,498 | $24,137 | 18.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 137 | 152 | $119,776 | $21,331 | 17.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 13 | 1,080 | $43,200 | $20,116 | 46.6% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 74 | 74 | $71,040 | $12,609 | 17.7% |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | Office | 2023 | 11 | 2,650 | $53,000 | $10,761 | 20.3% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 35 | 35 | $55,965 | $10,629 | 19.0% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 45 | 45 | $45,945 | $9,983 | 21.7% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 56 | 57 | $45,771 | $7,959 | 17.4% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 16 | 53 | $40,916 | $7,344 | 17.9% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 347 | 347 | $26,719 | $6,499 | 24.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 38 | 38 | $18,772 | $3,138 | 16.7% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2023 | 14 | 14 | $15,624 | $2,813 | 18.0% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2023 | 13 | 13 | $7,891 | $1,376 | 17.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 13 | 18 | $1,080 | $207.00 | 19.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 428 | 805 | $452,410 | $82,787 | 18.3% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 17 | 11,600 | $278,400 | $56,546 | 20.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 384 | 384 | $280,320 | $53,016 | 18.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 379 | 565 | $224,305 | $41,369 | 18.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 191 | 191 | $186,416 | $34,621 | 18.6% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 147 | 285 | $123,405 | $23,605 | 19.1% |
About Dr. Jennifer Buczyner, M.D
Dr. Jennifer Buczyner, M.D is a Neurology healthcare provider based in Jupiter, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/28/2007. The National Provider Identifier (NPI) number assigned to this provider is 1386841773.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jennifer Buczyner, M.D has received a total of $462,940 in payments from pharmaceutical and medical device companies, with $65,785 received in 2024. These payments were reported across 1,549 transactions from 72 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($345,938).
As a Medicare-enrolled provider, Buczyner has provided services to 8,383 Medicare beneficiaries, totaling 46,457 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 64 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Jupiter, FL
- Active Since 06/28/2007
- Last Updated 09/12/2023
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1386841773
Products in Payments
- SOLIRIS (Drug) $80,397
- Aimovig (Biological) $65,752
- UBRELVY (Drug) $52,437
- ULTOMIRIS (Biological) $42,283
- VYVGART (Drug) $26,452
- NURTEC ODT (Drug) $26,105
- KISUNLA (Drug) $17,092
- Soliris (Drug) $15,736
- TROKENDI XR (Drug) $12,313
- EMGALITY (Drug) $7,981
- REYVOW (Drug) $7,264
- Zilbrysq (Drug) $6,805
- Rystiggo (Drug) $5,408
- VYVGART HYTRULO (Drug) $2,628
- QULIPTA (Drug) $2,499
- Briviact (Drug) $2,169
- Adlarity (Drug) $1,185
- KESIMPTA (Drug) $1,083
- TYSABRI (Biological) $858.50
- KYPHON Balloon Kyphoplasty (Device) $661.80
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.